Exscientia Announces Closing of $510.4 Million Aggregate Financing, Consisting of $350.4 Million Upsized Initial Public Offering With Full Exercise of Underwriters' Option to Purchase Additional ADSs and $160.0 Million Concurrent Private Placement
Exscientia plc (Nasdaq: EXAI), an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner, today announced the